Table 4.
Factors Associated With Viral Suppression, After Model Implementation, Patient-centered Human Immunodeficiency Virus Care Model—United States, 2014–2016
| Bivariatea | Multivariableb (n = 461) | |||
|---|---|---|---|---|
| Characteristic | AOR (95% CI) | P Value | AOR (95% CI) | P Value |
| Age ≥50 y (n = 635)c,d | 1.91 (1.12–3.32) | .020 | … | |
| Black, non-Hispanic race/ethnicity (n = 509)d,e | 0.26 (.13-.49) | < .001 | 0.29 (.12-.62) | .002 |
| Male sex (n = 635)d | 2.02 (1.20–3.40) | .008 | … | |
| Private insurance (n = 578)d,f | 3.73 (1.62–10.2) | .004 | … | |
| Modified PDC (n = 582)d,g | 1.89 (1.46–2.45) | < .001 | 1.74 (1.30–2.34) | < .001 |
| Baseline HIVVL <200 copies/mL (n = 635)d | 11.0 (6.74–18.4) | < .001 | 7.69 (3.96–15.7) | < .001 |
| ≥1 adherence support (n = 564)d,h | 0.65 (.34–1.27) | .199 | … | |
| ≥1 pharmacist-patient action plan (n = 564)d,h | 0.85 (.50–1.46) | .561 | … | |
| ≥1 pharmacist-clinic action plan (n = 564)d,h | 0.25 (.04-.90) | .069 | … | |
| ≥3 pharmacist encounters (n = 559)d,h | 0.88 (.67–1.15) | .343 | … | |
Abbreviations: AOR, adjusted odds ratio; CI, confidence interval; HIV, human immunodeficiency virus; PDC, proportion of days covered; VL, viral load.
Each bivariate logistic regression model controlled for baseline viral suppression (HIV RNA <200 copies/mL).
Multivariate logistic regression.
Persons aged ≥50 years were compared with persons aged <50 years.
Transgender persons were excluded from the analyses due to small numbers.
Non-Hispanic black persons were compared with all other races/ethnicities combined.
Persons with private insurance were compared to persons without private insurance.
PDC was modified to account for the time to the last viral load in the postimplementation measurement period.
Separate multivariable models were conducted for each model intervention category and for number of pharmacist encounters. Each of the separate models contained demographic factors, modified PDC, and baseline viral suppression.